TG Therapeutics, Inc. (NASDAQ:TGTX) Files An 8-K Results of Operations and Financial Condition

TG Therapeutics, Inc. (NASDAQ:TGTX) Files An 8-K Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition.

On August 9, 2019, TG Therapeutics, Inc. (“TG” or the “Company”) issued a press release announcing results of operations for the three and six months ended June 30, 2019. The Company will host an investor conference call today, August 9, 2019, at 8:30am ET, during which the Company will provide a brief overview of its second quarter financial results and provide a business outlook for the remainder of 2019. A copy of such press release is being furnished as Exhibit 99.1.
Item 9.01 Financial Statements And Exhibits.
(d) Exhibits.
99.1
Press release issued by TG Therapeutics, Inc., dated August 9, 2019.
TG THERAPEUTICS, INC. Exhibit
EX-7 2 v080919_ex991.htm EXHIBIT 99.1 Blueprint Exhibit 99.1 TG Therapeutics Provides Business Update and Reports Second Quarter 2019 Financial Results   Conference call to be held today,…
To view the full exhibit click here

Story continues below

About TG Therapeutics, Inc. (NASDAQ:TGTX)

TG Therapeutics, Inc. (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for b-cell malignancies and autoimmune diseases. The Company is developing over two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the CD20 antigen found on mature B-lymphocytes. The Company is also developing TGR-1202, an orally available Phosphoinositide 3-kinase (PI3K) delta inhibitor. Both TG-1101 and TGR-1202 are in clinical development for patients with hematologic malignancies. The Company also has pre-clinical programs focusing on developing interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitors and anti-PD-L1 and anti-GITR antibodies. The Company also evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition and investment opportunities.

An ad to help with our costs